TipRanks
Bioxcel Therapeutics (BTAIQ)
OTHER OTC:BTAIQ
US Market
BTAIQ
Bioxcel Therapeutics
RESEARCH TOOLSreports
Want to see BTAIQ full AI Analyst Report?

Bioxcel Therapeutics (BTAIQ) Stock Forecast & Price Target

1,945 Followers
See the Price Targets and Ratings of:

BTAIQ Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Bioxcel
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BTAIQ Stock 12 Month Forecast

There Are No Analyst Ratings for BTAIQ In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

BTAIQ Financial Forecast

BTAIQ Earnings Forecast

Next quarter’s earnings estimate for BTAIQ is -$1.01 with a range of -$1.01 to -$1.01. The previous quarter’s EPS was -$0.49. BTAIQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BTAIQ has Performed in-line its overall industry.
Next quarter’s earnings estimate for BTAIQ is -$1.01 with a range of -$1.01 to -$1.01. The previous quarter’s EPS was -$0.49. BTAIQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BTAIQ has Performed in-line its overall industry.

BTAIQ Sales Forecast

Next quarter’s sales forecast for BTAIQ is $191.00K with a range of $191.00K to $191.00K. The previous quarter’s sales results were $182.00K. BTAIQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BTAIQ has Performed in-line its overall industry.
Next quarter’s sales forecast for BTAIQ is $191.00K with a range of $191.00K to $191.00K. The previous quarter’s sales results were $182.00K. BTAIQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BTAIQ has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BTAIQ
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$5
Buy
575.68%
Upside
Reiterated
04/10/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Bioxcel Therapeutics (NASDAQ: BTAI)
Bank of America Securities Analyst forecast on BTAIQ
Alec Stranahan
Bank of America Securities
Bank of America Securities
$1
Sell
35.14%
Upside
Reiterated
03/27/26
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)
Rodman & Renshaw Analyst forecast on BTAIQ
Michael King
Rodman & Renshaw
Rodman & Renshaw
$17
Buy
2197.30%
Upside
Initiated
03/17/26
BioXcel Therapeutics initiated with a Buy at Rodman & RenshawBioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BTAIQ
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$5
Buy
575.68%
Upside
Reiterated
04/10/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Bioxcel Therapeutics (NASDAQ: BTAI)
Bank of America Securities Analyst forecast on BTAIQ
Alec Stranahan
Bank of America Securities
Bank of America Securities
$1
Sell
35.14%
Upside
Reiterated
03/27/26
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)
Rodman & Renshaw Analyst forecast on BTAIQ
Michael King
Rodman & Renshaw
Rodman & Renshaw
$17
Buy
2197.30%
Upside
Initiated
03/17/26
BioXcel Therapeutics initiated with a Buy at Rodman & RenshawBioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VSTMVerastem
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bioxcel Therapeutics

3 Months
Alec StranahanBank of America Securities
Success Rate
7/9 ratings generated profit
78%
Average Return
-1.02%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of -1.02% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
5/6 ratings generated profit
83%
Average Return
+48.62%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +48.62% per trade.
2 Years
DeepSeek BiotechnologyTipRanks - DeepSeek
Success Rate
1/1 ratings generated profit
100%
Average Return
+11.00%
Copying DeepSeek Biotechnology's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +11.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BTAIQ Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
0
0
0
0
In the current month, BTAIQ has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BTAIQ average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

BTAIQ Stock Forecast FAQ

What is BTAIQ’s average 12-month price target, according to analysts?
Currently, no data Available
What is BTAIQ’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for BTAIQ, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is BTAIQ a Buy, Sell or Hold?
      Currently, no data Available
      What is Bioxcel Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Bioxcel Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of BTAIQ?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.